ArticleFrontiers in neurology2024
Thalamic volume differentiates multiple sclerosis from neuromyelitis optica spectrum disorder: MRI-based retrospective study.
Article in Frontiers in neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Brain atrophy in NMOSD and MOGAD: a meta-analysis of volumetric and DTI biomarkers.Frontiers in neurology · 2025Pooled it
- Microstructure-informed deep learning improves thalamic atrophy segmentation and clinical associations in multiple sclerosis and related neuroimmunological diseases.NeuroImage. Clinical · 2026Article
- IVIM-DWI-Based Radiomics for Lesion Phenotyping and Clinical Status Prediction in Relapsing-Remitting Multiple Sclerosis.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD) are distinct demyelinating diseases of the central nervous system, each characterized by unique patterns of motor, sensory, and visual dysfunction. While MS typically affects the brain and spinal cord, NMOSD predominantly targets the optic nerves and spinal cord. This study aims to elucidate the morphometric differences between MS and NMOSD by focusing on gray matter volume changes in specific brain regions. We also examined if temporal changes in follow-up MRI differentiate the two disorders. We analyzed anatomical T1-weighted MRI scans from 24 patients with NMOSD and 25 patients with MS using the CAT12 toolbox. Our analysis revealed significant differences in gray matter structure between the two patient groups. Notably, the thalamus was found to be consistently smaller in patients with MS compared to those with NMOSD. This finding aligns with previous research highlighting thalamic atrophy as a hallmark of MS and further underscores the thalamus's role in the disease's pathology. These results provide valuable insights into the distinct neuroanatomical features of MS and NMOSD, contributing to a better understanding of the mechanisms underlying these diseases. The study also emphasizes the importance of advanced imaging techniques in differentiating between MS and NMOSD, which may have implications for diagnosis and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.